Data from a randomized study suggest that drug–drug interactions reduce the efficacy of boceprevir (hepatitis C [HCV] medication) and ritonavir-boosted protease inhibitors (HIV medication) upon coadministration. 39 healthy adults received boceprevir for 6 days, followed by atazanavir, lopinavir, or darunavir for 25 days (plus ritonavir on days 10–31 and boceprevir on days 25–31). Concomitant administration of these anti-HCV and anti-HIV drugs resulted in significantly reduced exposure of both agents.
ORIGINAL RESEARCH PAPER
Hulskotte, E. G. et al. Pharmacokinetic interactions between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin. Infect. Dis. doi:10.1093/cid/cis968
Rights and permissions
About this article
Cite this article
Pharmacokinetic interactions between HCV and HIV drugs. Nat Rev Urol 10, 65 (2013). https://doi.org/10.1038/nrurol.2012.244
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.244
